MIVI Neuroscience Presents Primary Endpoint Results from the EvaQ Trial — at the 2024 International Stroke Conference
Primary effectiveness endpoint results show high revascularization rates of 93.9% mTICI 2b/3
Source: dicardiology.com
Bob Colloton News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Bob Colloton. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Bob Colloton Today - Breaking & Trending Today
Clinical Trial Enrollment Complete for Study of MIVI Q™ Revascularization System that Treats Acute Ischemic Stroke
/PRNewswire/ -- MIVI Neuroscience, Inc., innovator of next-generation neurointerventional medical devices, today announced that it has completed enrollment in...
Source: prnewswire.com
MIVI Neuroscience Launches Largest Study Yet of its Aspiration Catheter for Thrombus Removal
The AQUAS Registry is a prospective registry of 250 subjects conducted across up to 12 high-volume, comprehensive stroke centers in Europe.
Source: dicardiology.com
MIVI Neuroscience Secures Series B Funding
MIVI Neuroscience Secures Series B Funding News provided by Share this article Share this article EDEN PRAIRIE, Minn., Jan. 21, 2021 /PRNewswire/ -- MIVI Neuroscience, a medical device company focused on improving clinical outcomes for ischemic stroke patients, today announced the closing of its Series B funding including $35 million in new money plus the conversion of previously issued convertible notes. The funding was led by a major multinational med-tech company and included participation from new investors Perceptive Advisors, Deerfield Management and Aphelion / Cardeation Capital as ...
Source: prnewswire.com